InVivo Therapeutics Holdings Corp. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 2.283 million compared to USD 2.732 million a year ago. Net loss was USD 2.279 million compared to USD 2.679 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 8.63 a year ago. For the nine months, operating loss was USD 6.906 million compared to USD 8.758 million a year ago. Net loss was USD 6.882 million compared to USD 8.458 million a year ago. Basic loss per share from continuing operations was USD 2 compared to USD 27.25 a year ago.